GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » 50-Day SMA

HBPCF (Helix BioPharma) 50-Day SMA : $0.63 (As of Dec. 15, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-12-15), Helix BioPharma's 50-Day SMA is $0.63. It's 20-Day SMA is $0.45 and 200-Day SMA is $0.72.


Competitive Comparison of Helix BioPharma's 50-Day SMA

For the Biotechnology subindustry, Helix BioPharma's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's 50-Day SMA falls into.



Helix BioPharma  (OTCPK:HBPCF) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helix BioPharma  (OTCPK:HBPCF) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Helix BioPharma 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

Helix BioPharma Headlines

From GuruFocus

Helix BioPharma Corp. Closes Private Placement

By ACCESSWIRE ACCESSWIRE 12-31-2020

Helix Biopharma Corp. Reports Voting Results

By ACCESSWIRE ACCESSWIRE 01-29-2021

Helix BioPharma Corp. Provides Bi-Weekly MCTO Status Update

By ACCESSWIRE ACCESSWIRE 11-02-2021

Helix BioPharma Corp. Provides Corporate Update

By ACCESSWIRE ACCESSWIRE 12-31-2021

Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

By ACCESSWIRE ACCESSWIRE 12-23-2020

Helix Biopharma Corp. Announces Management and Board Changes

By ACCESSWIRE ACCESSWIRE 03-23-2022